FDA warned VitaStik that its oral inhalation sticks are unapproved new drugs marketed with claims to treat asthma, anxiety, sleep and other conditions.
What happened
FDA reviewed www.vitastik.com in September 2021 and social media pages that direct consumers to the site. FDA found the company takes orders for oral inhalation VitaStik products and that website and social media claims show they are intended to treat conditions such as asthma, anxiety, PTSD, insomnia and allergies. FDA also said the products are not dietary supplements because labeling instructs inhalation, not ingestion, and cited safety concerns for oral inhalation ingredients.
What FDA found
FDA says the products are unapproved new drugs because they are intended to treat disease and no FDA-approved applications are in effect.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d); section 201(p), 21 U.S.C. 321(p)FDA says the products are not dietary supplements because they are intended for inhalation, not ingestion.
FD&C Act section 201(ff)(2)(A)(i), 21 U.S.C. 321(ff)(2)(A)(i)FDA says website and social media claims establish the products are intended to diagnose, cure, mitigate, treat or prevent disease or affect body structure or function.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)FDA says introducing or delivering the products into interstate commerce violates the FD&C Act.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA asks VitaStik to notify it in writing within 15 working days of the steps taken to address the violations, including an explanation of each step and copies of related documentation. If the company believes the products are not in violation, it must include its reasoning and supporting information; if it cannot finish within that time, it must state why and give a completion date.
Who should pay attention
- companies selling inhaled essential-oil or aromatherapy sticks with drug-like claims
- retailers and distributors offering VitaStik products
- brands marketing supplements for asthma, anxiety or sleep through websites and social media
This is a summary. Read the original letter on fda.gov.